{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:25:47Z","timestamp":1790652347917,"version":"4.1.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,15]]},"DOI":"10.2169\/internalmedicine.9282-21","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T22:14:16Z","timestamp":1668464056000},"page":"3323-3328","source":"Crossref","is-referenced-by-count":15,"title":["Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients"],"prefix":"10.2169","volume":"61","author":[{"given":"Yoko","family":"Edahiro","sequence":"first","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"},{"name":"Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Japan"},{"name":"Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumitsu","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"},{"name":"Department of Hematology, Ibaraki Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[{"name":"Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Japan"},{"name":"Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Juntendo University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marito","family":"Araki","sequence":"additional","affiliation":[{"name":"Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Japan"},{"name":"Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"},{"name":"Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Japan"},{"name":"Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 12: 409-432, 1975."},{"key":"2","unstructured":"2. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 23: 177-182, 1986."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 23: 339-347, 1997.","DOI":"10.1055\/s-2007-996107"},{"key":"4","unstructured":"4. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001."},{"key":"5","unstructured":"5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 \u00d7 10(9)\/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 100: 15-23, 1998.","DOI":"10.1046\/j.1365-2141.1998.00529.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl J Med 352: 1779-1790, 2005.","DOI":"10.1056\/NEJMoa051113"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148, 2005.","DOI":"10.1038\/nature03546"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149: 352-375, 2010.","DOI":"10.1111\/j.1365-2141.2010.08122.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol 167: 421-423, 2014.","DOI":"10.1111\/bjh.12986"},{"key":"13","unstructured":"13. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised 4th Edition. IARC, Lyon, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 369: 2379-2390, 2013.","DOI":"10.1056\/NEJMoa1311347"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 369: 2391-2405, 2013.","DOI":"10.1056\/NEJMoa1312542"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270, 2006.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets 17: 328-331, 2006.","DOI":"10.1080\/09537100600746573"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"19","unstructured":"19. Dame C. Pediatric hematology. 3rd edition. Blackwell Publishing, Oxford, 2006."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bailey SE, Ukoumunne OC, Shephard E, Hamilton W. How useful is thrombocytosis in predicting an underlying cancer in primary care? a systematic review. Fam Pract 34: 4-10, 2017.","DOI":"10.1093\/fampra\/cmw100"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW. Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes. J Clin Med Res 4: 415-423, 2012.","DOI":"10.4021\/jocmr1125w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 245: 295-300, 1999.","DOI":"10.1046\/j.1365-2796.1999.00452.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nguyen E, Harnois M, Busque L, et al. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Blood Cancer J 11: 75, 2021.","DOI":"10.1038\/s41408-021-00463-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/22\/61_9282-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:30:46Z","timestamp":1715315446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/22\/61_9282-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":23,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9282-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"9282-21"}}